Actively Recruiting
Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)
Led by Sun Yat-sen University · Updated on 2025-02-10
47
Participants Needed
2
Research Sites
252 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of golidocitinib and benmelstobart combination treatment in patients with relapsed or refractory extranodal natural killer/T cell lymphoma.
CONDITIONS
Official Title
Phase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Understand and agree to participate in the study by signing informed consent
- Confirmed diagnosis of extranodal natural killer/T cell lymphoma (ENKTL)
- Aged 18 years or older, any gender
- Have failed at least one line of asparaginase-based therapy
- Eastern Cooperative Oncology Group performance status of 0 to 2
- Expected survival of 3 months or more
- Have at least one measurable lesion according to Lugano 2014 criteria
- Have sufficient organ function
You will not qualify if you...
- Diagnosis of invasive NK-cell leukemia or NKTCL progressed to leukemia
- Presence of hemophagocytic lymphohistiocytosis
- NKTCL with central nervous system involvement
- Previous treatment with JAK inhibitors
- Contraindications to any drugs used in the combination treatment
- Infection with HIV or AIDS
- Inability to swallow tablets or gastrointestinal conditions affecting drug absorption
- Pregnant or breastfeeding women or those not willing to use contraception if of childbearing potential
- Mental illness or inability to provide informed consent as judged by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Beijing Tongren Hospital
Beijing, Beijing Municipality, China, 100730
Actively Recruiting
2
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060
Actively Recruiting
Research Team
Q
Qingqing Cai, MD. PhD.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here